Purple Biotech (PPBT) - Long-Term Debt to Capital

Purple Biotech (PPBT) is developing oncology treatment methods, leveraging stable demand despite sanction risks regarding raw material supplies. Patient safety is ensured through strictly controlled transportation of components. Engaging external CRO partners for testing does not create dependency, as the formulas are patent-protected. The asset's market dynamics, where the indicator stands at 0.00, confirm the resilience of this fundamental business model.

Long-term debt-to-equity assesses financial stability through the reliance on external borrowings with maturities exceeding one year. By analyzing the dynamics of the long-term debt-to-equity ratio, an investor can determine the proportion of credit obligations relative to equity. The coefficient is calculated by dividing the total amount of long-term loans by the total shareholders' equity. An increase in this metric for Purple Biotech (PPBT) may indicate the financing of costly developments in targeted cancer therapy. Monitoring this metric is critical when creating innovative drugs to combat resistant tumors.